Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced advancements in its spatial biology portfolio, featuring the RNAscope™ ISH technology and Lunaphore COMET™ platforms. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, bridging translational research and clinical applications.
The company will showcase these technologies at the National Society of Histotechnology Convention (September 26-30), featuring presentations on RNAscope's application in B-cell clonality assessment and COMET's capabilities in lymphoid malignancy profiling using a 21-plex seqIF™ panel. Bio-Techne is also advancing its partnership with Leica Biosystems, co-hosting a reception to demonstrate RNAscope assays on Leica BOND platforms.
Positive
- Development of advanced spatial biology tools for simultaneous RNA and protein detection
- Integration potential into diagnostic workflows, especially for limited tissue samples
- Partnership advancement with Leica Biosystems for platform compatibility
Negative
- Products are currently For Research Use Only, not approved for diagnostic procedures
- Analytical and performance characteristics for IGLL5 probe not yet established
Insights
Bio-Techne advances spatial biology technologies that could strengthen their position in the translational and clinical markets.
Bio-Techne has announced significant advancements in their spatial biology portfolio, specifically for their RNAscope™ ISH technology and the Lunaphore COMET™ platform. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, creating a powerful bridge between translational research and potential clinical applications.
The technical capabilities highlighted are particularly noteworthy. RNAscope™ can detect clinically relevant biomarkers like viral markers, secreted proteins, point mutations, and chromosomal translocations within standard pathology workflows. Meanwhile, COMET™ offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, which accelerates spatial multiomic workflows.
The company is showcasing these technologies at the National Society of Histotechnology Convention with multiple presentations highlighting potential clinical applications. The studies presented include using RNAscope™ for B-cell clonality assessment and COMET™ for spatial profiling of lymphoid malignancies with a 21-plex seqIF™ panel.
These advancements position Bio-Techne to potentially capture more market share in the rapidly growing spatial biology sector, especially as these technologies demonstrate utility in diagnostic workflows where tissue samples are limited. While both technologies are currently labeled
Bio-Techne's continued partnership with Leica Biosystems for RNAscope assays on Leica BOND platforms further strengthens their distribution capabilities and market penetration potential in clinical and research laboratories that already use Leica equipment.
- RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section
- Technologies support spatial multiomic analysis and deeper insights for pathology workflows
- Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality
RNAscope™ empowers pathologists and histologists to detect clinically relevant biomarkers—such as viral markers, secreted proteins, point mutations, and chromosomal translocations—within routine anatomic pathology workflows. COMET™ offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights.
Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™ for assessing B-cell clonality with IGLL5 detection, and COMET™ for spatial profiling of lymphoid malignancies using a 21-plex seqIF™ panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability.
Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26–30 in
Presentations include:
- RNAscope™ for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™ over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.)
- RNAscope™ of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™ for assessing B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. (Poster #6038, Sep. 30, 9:05–9:20 a.m.)
- seqIF™ Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. (Poster #6043)
Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Parker's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.
"We are thrilled by the progress we've made in advancing traditional in situ hybridization," said Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By working hand-in-hand with our customers and learning from the exceptional speakers at NSH, we are creating innovative tools that bring us closer to unlocking the molecular drivers of disease and transforming patient care."
Disclaimer:
The RNAscope probe for IGLL5 is an Analyte Specific Reagent. Analytical and performance characteristics have not been established.
RNAscope and COMET are For Research Use Only. Not for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact:
Corporate Communications
media.relations@bio-techne.com
David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-advances-spatial-biology-solutions-bridging-translational-research-to-clinical-applications-302568115.html
SOURCE Bio-Techne Corporation
FAQ
What new technologies did Bio-Techne announce for spatial biology?
What are the key applications of Bio-Techne's RNAscope technology?
How does the COMET platform benefit research workflows?
When and where will Bio-Techne showcase these technologies?
Are Bio-Techne's new spatial biology tools approved for clinical diagnosis?
